A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred with High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Protocol No
JANSSEN-42756493BLC2003-THOR-2
Principal Investigator
Scott Johnson
Phase
II
Summary
The purpose of this study is to see if Erdafitinib is safe and useful for treating patients with highrisk NMIBC that recurred (came back) after BCG therapy and has a gene mutation or fusion in the gene called FGFR, or fibroblast growth factor receptor. The study drug in this protocol is called Erdafitinib. It is a FGFR inhibitor, which means this study drug will bind to the altered FGFR receptor and block its activation, thereby causing the cancer cells to die.
Description
Erdafitinib vs Investigator Choice of Intravesical Chemo for NMIBC Pts Who Recurred After BCG
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL